Category Specific RSS

Categories: News

Testing confirms infection resistance, First Graphene signs face mask supply deal

As world populations seek increased protection from airborne infections, advanced materials company First Graphene (ASX: FGR) has completed initial testing of their graphene as coating into protective equipment with excellent results. 

The testing was done in collaboration with planarTECH and their personal protective equipment (PPE) which confirmed anti-static and bacteria-resistant properties. With these results, planarTECH has entered into a 2-year supply contract to use  PureGRAPH® in their 2AM brand face masks. 

“planarTECH have moved very quickly to test and commercialise their new range of graphene face masks and we are pleased to support the growth of this product. Further opportunities exist in the development of planarTECH’s other PPE equipment,” said First Graphene CEO, Craig McGuckin. 

Having secured the supply agreement, planarTech will commence large-scale production of their protective face marks which will be coated with PureGRAPH®10.

Under terms of the agreement, First Graphene will supply one tonne of PureGRAPH®10 through each year of the agreement. 

“We have experienced substantial, rapid and qualified enquiries for the graphene mask,” said planarTECH Chairman, Ray Gibbs.  

“The 35 or so we are pursuing all require a fast turnaround of 2-3 weeks where potential orders could be very significant. This increasing demand has meant we needed to secure a robust graphene supply to ensure we met the known market demand.”

Produced out of First Graphene’s West Australian manufacturing facility, graphene powders are high-performance additives which are engineered byproducts of graphite which boast its strongest properties – strength, conductivity and lubrication – but as a significantly thinner single-layer material. 

Upon news of the supply agreement, FGR shares rose to a high of $0.15 in the first 30 minutes of morning trade, a 15% rise on their previous day close of $0.13.

Alfred Chan

Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.

Recent Posts

Control Bionics Moves to Fully Acquire NeuroBounce Program as EMG-Based Performance Tech Gains Momentum

As interest in neuromuscular activation tools accelerates across elite sport, Control Bionics Limited (ASX:CBL) is…

10 hours ago

SKS Technologies Moves to Expand NSW Footprint With Delta Elcom Acquisition

Australia’s data-centre construction sector continues to surge on the back of cloud adoption, AI-driven computing…

2 weeks ago

Monash University Partners with HITIQ to Advance Concussion Science Using Smart Mouthguards

A major Australian research initiative is set to push forward global understanding of brain injury,…

4 weeks ago

Harris Technology targets return to profitability amid surging Refurbished Tech sales and Apple expansion

Following a successful FY25 which saw a boost in gross profit after launching its refurbished…

1 month ago

Pivotal Metals Secures $5.4M to Fast-Track Quebec Drill Program

Pivotal Metals (ASX:PVT) has locked in $5.4 million in fresh funding to accelerate exploration across…

1 month ago

Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise

Biotech company Biotron Limited (ASX:BIT) has announced a bold step into the anaesthetics sector, acquiring…

2 months ago